{Reference Type}: Journal Article
{Title}: Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials.
{Author}: Kuang X;Xu R;Li J;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 198
{Issue}: 0
{Year}: 2024 Jun 16
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104357
{Abstract}: <B>BACKGROUND: </B>Whether PD-L1 testing is needed to identify patients receiving PD-1/PD-L1 inhibitors is an area of debate.<BR><B>METHODS: </B>PubMed and Embase were searched for phase III randomized clinical trials. We assessed the heterogeneity of overall survival (OS) between patients with high and low PD-L1 expression using an interaction test.<BR><B>RESULTS: </B>Seventy studies representing 44791 patients were included. Both the CPS and TPS can predict better survival from anti-PD-1/PD-L1 therapy in patients with high PD-L1 expression. However, only CPS 1 has the ability to select patients who are unlikely to respond to anti-PD-1/PD-L1 therapy, while an OS advantage can be obtained from PD-1/PD-L1 inhibitors both in patients with high and low PD-L1 expression defined by CPS 5, CPS 10 and TPS.<BR><B>CONCLUSIONS: </B>CPS 1 is recommended to select patients with the likelihood of benefiting from PD-1/PD-L1 inhibitors while excluding patients who may not respond.